Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Returns
Return on equity-27.3%+58.0pp-24.7%+42.9pp-38.5%-7.4pp-85.3%-30.7pp
Return on assets-26.4%+56.1pp-23.8%+41.5pp-34.6%-8.5pp-80.7%+4.2pp-82.5%-29.9pp
Return on invested capital-37%-32.6%-50.1%
Liquidity
Current ratio23.8×-6.3×22.4×-6.5×16.9×-6.0×27.4×+0.8×30×+30.0×
Quick ratio23.8×-6.3×22.4×-6.5×16.9×-6.0×27.4×+0.8×30×+30.0×
Cash ratio-4.2×3.1×-1.7×4.4×+2.2×5.4×-6.5×7.1×-10.4×
Leverage
Debt-to-equity0.0×0.0×0.0×-48.0×
Debt-to-assets0.0×0.0×0.0×0.0×-48.0×
Valuation
Market capitalization$2.43B+533%$1.47B+116%$930.43M$440.3M$384.14M
Enterprise value$2.38B+690%$1.42B+130%$841.09M$377.23M$301.51M
Price / book+3.9×3.1×+1.3×1.9×1.3×1.1×
Free cash flow yield-3.8%-6%-13.3%-32.1%
Earnings yield-4.8%+35.7pp-7.2%+13.7pp-17.2%-35.9%-40.5%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Oruka Therapeutics, Inc.'s ratios come from?
Every ratio is computed from Oruka Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.